Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: January 27, 2022

DrugPatentWatch Database Preview

Details for Patent: 10,065,952

Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,065,952
Title:Valbenazine salts and polymorphs thereof
Abstract: Provided herein are salts of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[- 2,1-a]isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of neurological disorders and diseases including hyperkinetic movement disorders or diseases.
Inventor(s): McGee; Kevin (San Diego, CA), Zook; Scott (San Diego, CA), Carr; Andrew (Cambridge, GB), Bonnaud; Thierry (Cambridge, GB)
Assignee: Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:15/338,214
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,065,952
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 10,065,952

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-001 Apr 11, 2017 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y TREATMENT OF TARDIVE DYSKINESIA ⤷  Try it Free
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-003 Apr 23, 2021 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y TREATMENT OF TARDIVE DYSKINESIA ⤷  Try it Free
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-002 Oct 4, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y TREATMENT OF TARDIVE DYSKINESIA ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,065,952

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2016343633 ⤷  Try it Free
Brazil 112018008460 ⤷  Try it Free
Canada 3002074 ⤷  Try it Free
Chile 2018001089 ⤷  Try it Free
China 108473489 ⤷  Try it Free
Colombia 2018004589 ⤷  Try it Free
Denmark 3368534 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.